Tomida Kaori, Kawai Yuki, Mori Tsuyoshi, Kitamura Mina, Kato Hisataka, Sakai Sachiko, Shimizu Tomoharu, Umeda Tomoko, Tatsumi Masahiro, Shimada Kana, Tani Masaji
Dept. of Surgery, Shiga University of Medical Science.
Gan To Kagaku Ryoho. 2018 Dec;45(13):2435-2437.
Combination chemotherapy with pertuzumab, trastuzumab, and docetaxel is recommended as the first-line treatment for patients with HER2-positive unresectable or metastatic breast cancer. We report 2 cases of unresectable breast cancer for which pertuzumab, trastuzumab, and docetaxel therapy was effective. Case 1: A woman in her 40s was diagnosed with TxN3aM0, Stage ⅢC, HER2-positive, hormone receptor-positive advanced breast cancer. After administration of 6 courses of pertuzumab, trastuzumab, and docetaxel therapy, she underwent surgery(Bt+Ax[Ⅱ]). Histopathological examination revealed that chemotherapy effect was Grade 3. Case 2: A woman in her 60s was diagnosed with de novo Stage Ⅳ, HER2- positive, hormone receptor-negative breast cancer. She was administered 8 courses of pertuzumab, trastuzumab, and docetaxel therapy as the third-line treatment, because she initially refused treatment. Thereafter, she underwent surgery(Bt+Ax [Ⅰ]). In both cases, histopathological examination revealed complete response after chemotherapy. Thus, combination therapy of pertuzumab and trastuzumab may improve the prognosis in patients with HER2-positive breast cancer.
帕妥珠单抗、曲妥珠单抗和多西他赛联合化疗被推荐作为HER2阳性不可切除或转移性乳腺癌患者的一线治疗方案。我们报告了2例不可切除乳腺癌患者，帕妥珠单抗、曲妥珠单抗和多西他赛治疗对其有效。病例1：一名40多岁的女性被诊断为TxN3aM0，ⅢC期，HER2阳性，激素受体阳性的晚期乳腺癌。在接受6个疗程的帕妥珠单抗、曲妥珠单抗和多西他赛治疗后，她接受了手术（保乳手术+腋窝淋巴结清扫[Ⅱ级]）。组织病理学检查显示化疗效果为3级。病例2：一名60多岁的女性被诊断为初发Ⅳ期，HER2阳性，激素受体阴性乳腺癌。由于她最初拒绝治疗，作为三线治疗，她接受了8个疗程的帕妥珠单抗、曲妥珠单抗和多西他赛治疗。此后，她接受了手术（保乳手术+腋窝淋巴结清扫[Ⅰ级]）。在这两个病例中，组织病理学检查均显示化疗后完全缓解。因此，帕妥珠单抗和曲妥珠单抗联合治疗可能改善HER2阳性乳腺癌患者的预后。
